Vascular Biogenics (VBLT) Downgraded to “Neutral” at Piper Jaffray Companies
Piper Jaffray Companies downgraded shares of Vascular Biogenics (NASDAQ:VBLT) from an overweight rating to a neutral rating in a research report report published on Thursday, Marketbeat reports. The brokerage currently has $4.00 price objective on the biopharmaceutical company’s stock.
A number of other equities analysts have also recently commented on the stock. HC Wainwright cut shares of Vascular Biogenics from a buy rating to a neutral rating and set a $3.00 price target for the company. in a research note on Thursday. Zacks Investment Research cut shares of Vascular Biogenics from a hold rating to a sell rating in a research note on Friday, February 23rd. Finally, ValuEngine raised shares of Vascular Biogenics from a sell rating to a hold rating in a research note on Friday, February 2nd. Two research analysts have rated the stock with a sell rating and four have assigned a hold rating to the stock. The company presently has a consensus rating of Hold and a consensus price target of $3.33.
Vascular Biogenics (NASDAQ:VBLT) traded down $0.05 during trading on Thursday, reaching $2.60. 1,134,183 shares of the company were exchanged, compared to its average volume of 568,487. The company has a market cap of $77.28, a price-to-earnings ratio of -3.29 and a beta of -2.44. Vascular Biogenics has a twelve month low of $2.30 and a twelve month high of $9.05.
TRADEMARK VIOLATION WARNING: “Vascular Biogenics (VBLT) Downgraded to “Neutral” at Piper Jaffray Companies” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international trademark and copyright law. The original version of this piece of content can be read at https://www.thecerbatgem.com/2018/03/11/vascular-biogenics-vblt-downgraded-to-neutral-at-piper-jaffray-companies.html.
Vascular Biogenics Company Profile
Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.
Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.